Stock listing

KRX:068760 Celltrion Pharm Inc. (셀트리온제약) 주가

Follow Celltrion Pharm Inc. into a list and get an email when it puts out news.

Share price · KRX:068760

₩40,650 KRW +400 (+1.0%)

Close on Nov 20, 2026

Past year -33.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩40,500 – ₩41,250 KRWNov 20, 2026
Volume
44,287 sharesNov 20, 2026
Market cap
₩1.80T KRWAt the close on Nov 20, 2026 · price × 44.26M shares outstanding
52-week range
₩35,600 – ₩78,300 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩2.89B KRWMedian day 60,470 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Celltrion Pharm Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:068760 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩40,650+400+1.0%₩41,150₩41,250₩40,50044,287
₩40,250-750-1.8%₩40,650₩41,700₩40,15064,961
₩41,000+600+1.5%₩40,400₩41,900₩40,30070,536
₩40,400-700-1.7%₩41,500₩41,950₩39,95078,209
₩41,100+850+2.1%₩41,100₩42,500₩40,85085,040
₩40,250-1,050-2.5%₩41,050₩42,000₩40,25072,901
₩41,300+1,700+4.3%₩40,000₩43,000₩39,950156,191
₩39,600+200+0.5%₩39,900₩41,275₩39,35090,006
₩39,400-200-0.5%₩39,300₩40,950₩39,150112,602
₩39,600-750-1.9%₩38,450₩40,500₩38,050125,783
₩40,350+2,500+6.6%₩39,000₩40,450₩38,650154,060
₩37,850+1,150+3.1%₩37,250₩37,850₩36,25068,863
₩36,700-350-0.9%₩36,700₩37,450₩36,55033,809
₩37,050+400+1.1%₩36,550₩37,450₩36,20023,317
₩36,650-150-0.4%₩36,650₩37,600₩36,00037,398
₩36,800-300-0.8%₩37,450₩37,500₩36,30047,099
₩37,100+550+1.5%₩36,700₩37,600₩36,70033,016
₩36,550+50+0.1%₩36,750₩37,550₩36,20051,525
₩36,500-1,100-2.9%₩37,150₩37,600₩36,45039,896
₩37,600-1,000-2.6%₩38,200₩38,250₩37,55041,591
₩38,600-750-1.9%₩38,950₩39,800₩38,40056,304
₩39,350-50-0.1%₩40,250₩40,850₩39,10047,696
₩39,400-600-1.5%₩39,500₩40,550₩39,35059,449
₩40,000+1,100+2.8%₩38,600₩40,000₩38,55047,021
₩38,900+2,350+6.4%₩36,550₩39,550₩36,55093,803
₩36,550-800-2.1%₩36,650₩36,950₩35,60082,216
₩37,350-200-0.5%₩37,200₩38,150₩37,15056,922
₩37,550-750-2.0%₩36,950₩37,850₩36,40092,504
₩38,300-500-1.3%₩38,950₩39,800₩38,20057,212
₩38,800-1,300-3.2%₩39,850₩40,500₩38,80052,164
₩40,100+450+1.1%₩39,950₩40,600₩39,70045,381
₩39,650+1,250+3.3%₩38,650₩40,150₩38,60080,558
₩38,400-1,250-3.2%₩39,500₩39,750₩38,25099,025
₩39,650+1,550+4.1%₩37,900₩39,650₩37,800120,590
₩38,100-500-1.3%₩38,500₩38,650₩37,95091,304
₩38,600-750-1.9%₩39,300₩39,300₩38,050116,563
₩39,350+300+0.8%₩39,250₩39,900₩38,900113,068
₩39,050+250+0.6%₩38,950₩39,200₩38,70034,703
₩38,800-700-1.8%₩39,550₩39,750₩38,75037,004
₩39,500+400+1.0%₩39,150₩39,700₩38,90040,072
₩39,100-100-0.3%₩39,700₩39,800₩38,400400,420
₩39,200+400+1.0%₩38,850₩39,300₩38,70046,546
₩38,800-450-1.1%₩39,300₩39,450₩38,75042,153
₩39,250-150-0.4%₩39,150₩40,000₩39,10041,184
₩39,40000.0%₩38,800₩39,700₩38,60053,996
₩39,400-600-1.5%₩39,400₩39,900₩39,15068,923
₩40,000-250-0.6%₩39,800₩40,300₩39,65078,378
₩40,250+250+0.6%₩39,900₩40,350₩39,70043,630
₩40,000-550-1.4%₩40,550₩40,800₩40,00059,182
₩40,550-300-0.7%₩41,250₩41,250₩40,35043,795
₩40,85000.0%₩41,050₩41,900₩40,75047,726
₩40,850-300-0.7%₩41,550₩42,000₩40,75053,601
₩41,150-400-1.0%₩41,300₩42,150₩40,65077,116
₩41,550-150-0.4%₩41,650₩42,150₩41,30061,490
₩41,700-900-2.1%₩42,200₩42,200₩40,85098,719
₩42,600+600+1.4%₩41,700₩42,800₩41,50047,920
₩42,000-550-1.3%₩42,200₩42,950₩41,95077,021
₩42,550+550+1.3%₩42,200₩42,800₩41,90063,646
₩42,000-800-1.9%₩41,800₩42,800₩41,05067,471
₩42,800+1,250+3.0%₩41,600₩43,350₩41,60074,974
₩41,550-1,400-3.3%₩42,150₩42,200₩40,90056,219
₩42,950+1,800+4.4%₩42,550₩43,350₩42,15065,190

Splits

7 splits since 2014 · KRX:068760 · every price before a split is adjusted for it

DayRatioWhat
21-for-20Split
21-for-20Split
51-for-50Split
21-for-20Split
21-for-20Split
103-for-100Split
21-for-20Split
Ticker
KRX:068760
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
KRX
Currency
KRW

Latest news

All Celltrion Pharm Inc. news

Celltrion Pharm Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
3 in all · newest Sep 17, 2025 · oldest 2019

Valuation

P/E 42.0× against a median of 23.6×: 6th lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩1.68T KRW
P/E
42.0×
EV/sales
2.9×
EV/EBITDA
19.6×
Price/book
4.0×
Gross margin
31.1%
Operating margin
10.7%
Net margin
7.4%
Debt to equity
0.0×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Celltrion Pharm Inc. · KRX:068760US$1.34BUS$1.25B42.0×2.9×19.6×4.0×7.4%0.0×n/a
Zhejiang Medicine Co., Ltd. Class A · SSE:600216US$1.47BUS$973.2M15.5×0.8×n/a0.8×7.5%0.0×n/a
Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675US$1.46BUS$1.41B46.5×3.6×n/a2.2×8.0%0.1×n/a
Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637US$1.45BUS$1.27B54.6×14.6×41.3×5.8×30.4%0.0×n/a
Marksans Pharma Limited · NSE:MARKSANSUS$1.42BUS$1.35B23.6×3.7×16.0×4.0×16.5%0.1×n/a
Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020US$1.40BUS$1.23B13.2×2.0×n/a1.6×17.5%0.0×n/a
Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319US$1.37BUS$1.39Bn/a11.7×n/a10.2×−4.0%0.4×n/a
Innoviva, Inc. · NASDAQ:INVAUS$1.33BUS$998.8M6.9×2.3×4.7×1.2×44.1%0.2×0.29
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A · SZSE:300026US$1.30BUS$1.07Bn/an/an/a1.0×n/a0.0×n/a
Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A · SZSE:002099US$1.30BUS$1.17Bn/a3.9×n/a1.9×−11.6%0.0×n/a
Concord Biotech Ltd. · NSE:CONCORDBIOUS$1.24BUS$1.19B40.6×9.4×27.3×5.5×24.1%0.0×n/a
Median of the othersUS$1.39BUS$1.21B23.6×3.7×21.6×2.0×16.5%0.0×0.29

Events

QuarterResultsShare move
Q1 2026May 13, 2026 · Before open−2.7%
Q4 2025Mar 16, 2026 · Before open−1.6%
Q2 2025Aug 12, 2025 · Before open−0.2%
Q1 2025May 15, 2025 · Before open−0.5%
Q4 2024Mar 17, 2025 · After close+0.9%
Q2 2024Aug 14, 2024 · After close−1.8%
Q1 2024May 16, 2024 · After close−2.9%
Q4 2023Mar 18, 2024 · After close+1.6%
Q3 2023Nov 14, 2023 · After close+9.5%
Q2 2023Aug 13, 2023 · After close−9.2%
All 20 quarters
QuarterResultsShare move
Q1 2023May 12, 2023 · After close−0.3%
Q4 2022Mar 20, 2023 · After close−1.4%
Q3 2022Nov 14, 2022 · After close+3.6%
Q2 2022Aug 16, 2022 · Before open+0.1%
Q1 2022May 13, 2022 · Before open−2.8%
Q4 2021Mar 8, 2022 · Before open+1.6%
Q3 2021Nov 15, 2021+14.6%
Quarter to Jun 30, 2021Aug 17, 2021+2.3%
Quarter to Mar 31, 2021May 14, 2021+2.8%
Quarter to Dec 31, 2020Mar 18, 2021−1.4%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue536.4B477.8B388.8B386.0B398.7B233.6B173.5B146.9B135.9B104.8B
Cost of revenue372.6B355.8B269.1B273.3B279.5B160.4B111.0B106.3B77.6B52.6B
Gross profit163.8B122.0B119.7B112.8B119.3B73.2B62.5B40.6B58.3B52.2B
Research and development19.1B13.0B12.7B8.00B6.37B4.61B2.16B1.92B1.03B1.20B
Selling, general and administrative41.9B68.1B68.2B65.5B64.1B43.5B43.9B33.8B47.3B42.4B
Operating income56.1B37.2B33.4B38.2B47.8B23.6B14.4B-332.9M8.67B7.27B
Depreciation and amortization22.2B19.2B18.7B16.8B15.8B13.5B13.0B12.7B12.2B8.99B
EBITDA78.3B56.5B52.1B54.9B63.6B37.1B27.5B12.4B20.9B16.3B
Interest expense6.67B7.51B8.29B6.22B5.36B4.58B5.04B000
Income before tax49.7B29.8B26.2B30.5B42.5B20.1B8.84B-6.26B2.46B571.8M
Income tax-811.8M242.7M3.13B-251.2M-2.34B
Net income38.8B22.0B21.3B26.0B34.6B20.9B8.60B-9.39B2.71B2.92B
Earnings per share, basic874.86505.39489.01596.73876.55557.20228.91-250.0172.3977.97

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents49.9B45.5B19.7B31.4B80.2B25.7B10.8B9.12B5.64B10.2B
Short-term investments67.1B18.0B12.5B12.7B7.97B4.00B2.57B315.0M315.0M
Receivables220.3B213.2B222.2B185.9B172.5B140.5B139.5B133.3B125.6B81.8B
Inventory122.9B101.4B100.4B69.2B63.9B55.0B33.1B42.0B65.2B78.9B
Current assets470.6B391.7B364.8B311.9B331.1B231.0B188.9B200.0B211.1B184.8B
Property, plant and equipment222.7B220.8B228.2B241.9B248.3B216.6B195.6B199.9B209.8B
Goodwill32.9B32.9B32.9B32.9B32.9B32.9B32.9B32.9B32.9B32.9B
Total assets759.4B669.5B641.6B599.7B637.9B548.1B471.0B452.4B470.3B510.0B
Accounts payable78.7B46.7B59.3B38.1B72.6B21.6B6.81B12.4B13.2B12.8B
Current liabilities283.6B247.7B249.3B212.0B259.9B184.9B149.1B145.0B124.3B72.4B
Long-term debt04.33B21.7B39.0B57.3B38.6B34.4B48.1B89.0B
Total debt178.9B147.8B133.2B137.4B138.7B
Total liabilities323.5B272.5B265.0B242.9B305.9B247.5B190.9B182.4B176.6B165.4B
Shareholders' equity436.0B396.9B376.7B356.8B332.0B300.6B280.0B270.0B293.6B344.6B
Shares outstanding44.3M43.5M43.5M43.5M39.4M37.6M37.6M37.6M37.5M37.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations86.4B56.6B8.76B-4.05B93.2B36.2B27.9B14.3B-10.2B-15.2B
Capital spending-17.9B-5.98B-6.90B-6.29B-12.5B-42.0B-30.5B-7.21B-1.08B-2.19B
Free cash flow68.5B50.6B1.86B-10.3B80.6B-8.01B-2.63B7.11B-11.2B-17.4B
Cash from investing-12.1B-4.22B-14.6B-16.3B-44.9B-34.5B-7.33B-1.01B-8.63B
Cash from financing-18.7B-16.2B-30.2B-22.4B23.6B8.26B-3.51B6.65B24.3B
Share buybacks-2.44B-4.05B-3.72B-3.71B-4.29B-832.2M255.8M-382.7M1.01B898.0M
Change in cash4.39B25.8B-11.7B-48.8B54.4B15.0B1.65B3.48B-4.56B493.1M

Open Financials

Cap table

Built by 6ix from Celltrion Pharm Inc.’s releases

Common shares
44,258,079
Fully diluted
44,258,079

Fully diluted

LineShares
Common shares44,258,079

Share count over time

CountShares
Nov 22, 202644,258,079

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund305KUS$8.54MJul 31, 2026
iShares Core MSCI Emerging Markets ETF214KUS$6.78MMay 31, 2026
Vanguard Developed Markets Index Fund189KUS$5.02MJun 30, 2026
Vanguard Ftse All-World Ex-Us Index Fund47,156US$1.32MJul 31, 2026
Schwab International Equity ETF44,308US$1.4MMay 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF39,131US$1.03MJun 30, 2026
Emerging Markets Core Equity 2 Portfolio38,917US$1.09MJul 31, 2026
iShares Core MSCI Total International Stock ETF29,939US$838KJul 31, 2026
Vanguard Pacific Stock Index Fund20,443US$572KJul 31, 2026
Vanguard Total World Stock Index Fund18,748US$525KJul 31, 2026
All 36 holders
HolderSharesValueAs of
The Emerging Markets Small Cap Series18,372US$514KJul 31, 2026
Franklin FTSE South Korea ETF15,244US$402KJun 30, 2026
Dimensional Emerging Markets Core Equity 2 ETF13,961US$394KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account12,984US$345KJun 30, 2026
Fidelity Total International Index Fund12,937US$358KJul 31, 2026
Avantis Emerging Markets Equity ETF9,698US$307KMay 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF7,553US$213KJul 31, 2026
Dimensional Emerging Core Equity Market ETF5,944US$168KJul 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF4,809US$152KMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio4,329US$114KJun 30, 2026
Vanguard ESG International Stock ETF3,680US$116KMay 31, 2026
Parametric Tax-Managed Emerging Markets Fund3,032US$80,509Jun 30, 2026
Avantis Emerging Markets Small Cap Equity ETF2,183US$69,070May 31, 2026
World ex U.S. Core Equity Portfolio2,156US$60,361Jul 31, 2026
Dimensional Emerging Markets Value ETF2,022US$57,014Jul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio1,605US$44,935Jul 31, 2026
Parametric Emerging Markets Fund1,516US$42,443Jul 31, 2026
Emerging Markets Social Core Equity Portfolio1,462US$40,931Jul 31, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund1,018US$28,704Jul 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF581US$16,382Jul 31, 2026
Destinations International Equity Fund473US$14,946May 31, 2026
Schwab International Opportunities Fund423US$11,843Jul 31, 2026
Avantis Emerging Markets ex-China Equity ETF314US$9,935May 31, 2026
Avantis Emerging Markets Equity Fund295US$9,334May 31, 2026
State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF116US$3,062Jun 30, 2026
Franklin FTSE Asia ex Japan ETF85US$2,244Jun 30, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Celltrion Pharm Inc.